GlassScriptPhysician profile
Jeff P Barone
NPI 1851620231
$1,959.39
in general payments reported to CMS, 2019-2025
26 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.81 · 2022: $367 · 2024: $351 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $230.77 | 2024-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $211.77 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $203.65 | 2024-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $182.18 | 2022-2025 | Freestyle Libre 3, Eterna |
| Exact Sciences Corporation | $169.81 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $141.55 | 2024-2025 | |
| Glaxosmithkline, LLC. | $101.78 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Actelion Pharmaceuticals US, INC. | $96.08 | 2022 | |
| Eisai INC. | $65.72 | 2025 | |
| Sumitomo Pharma America, INC. | $58.80 | 2024 | Gemtesa |
| Boston Scientific Corporation | $51.80 | 2024-2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Merck Sharp & Dohme LLC | $47.12 | 2025 | Gardasil 9, Capvaxive |
| Corcept Therapeutics | $45.22 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.11 | 2024-2025 | Xifaxan |
| Astellas Pharma US INC | $39.83 | 2025 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $38.46 | 2025 | Unithroid |
| Teva Pharmaceuticals USA, INC. | $35.53 | 2021-2025 | Ajovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.56 | 2025 | Caplyta |
| Lilly USA, LLC | $30.49 | 2022-2025 | Mounjaro |
| Inspire Medical Systems, INC. | $24.81 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $22.99 | 2025 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $22.60 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.04 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $17.02 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.24 | 2025 | Voquezna |
| Ibsa Pharma INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Barone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.